Sorrento Therapeutics post Zenith. SRNESpeculating end of A Wave, now in the beginning of an Elliott triangle or a variation of ABCDE pattern. Bearish. Early stage of pivot if real, as none of the volatility, parabolism, volume weight indicators have caught up yet. And it shows - I have not bothered to wait for confirmation. Agressive stance therfore.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
Sorrento
SRNE Start new rallie?I think that in final of August SRNE start a new rallie, I hope that start early than I think.
On the graph you can see my prediction lines :
Red -> Resistance that if overcome will become support.
Orange -> Our resistance lines that we try to broke, I think that will broke the bearish trend almost late Agust, September 1th and we take over the line of 9,5$ resistance. 9,5$ will pass to do our support.
Yellow -> Our bulish trend and our major resistance and support lines.
At that moment we will have a Golden Cross if the trend remains bullish, in addition the MACD indicator seems to want to turn around.
God luck to all!
Buy $SRNE - NRPicks 07 MarSorrento Therapeutics, Inc. is a commercial and clinically staged biopharmaceutical company, developing therapies for cancerous, autoimmune, inflammatory, viral and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex.
The company has been constantly adding new options to its bulky pipeline and has made two notable additions in the last month. Sorrento and its subsidiary Scilex are signing an exclusive licensing agreement with Aardvark Therapeutics to treat the post Covid chrononic chondrome.
The last move is that Sorrento is buying the outstanding assets of ANP Technologies for a total of $100 million, this acquisition will increase the additional capacity to produce COVID test kits and provide the know-how to optimize the test through the improvement of detection capabilities, thus conferring greater sensitivity and specificity".
Technical:
MACD Level (12, 26) 1.57
Low levels of RSI 35.78 Oversold
MA200 rebound
Price below MA 50 and MA100
AUDNZD short ideaAUDNZD was canceled because the bearish flag format in the previous analysis did not break. I will revise the new analysis and present it as follows. We can see that the AUD is weak at the moment, and the NZD is also weak at the moment, so we can assume that the AUDNZD must create a bearish wave. AUDNZD has so far rejected a strong supply zone. The bearish triple peak concept of the AO indicators is used to confirm the addition, the indicator shows a clear breakdown and keep in mind that the analysis is somewhat complicated and can be overturned at any time.
SRNE Falling WedgeI didn't want to publish this idea, but I put it public in case it comes true. I hope to get the end right.
I'm a beginner and I'm learning so I accept any comments.
No quería publicar esta idea, pero la pongo pública por si se cumple. Espero acertar el final.
Soy novato y estoy aprendiendo así que acepto cualquier comentario al respeto.
Big Pharma comparative analysis ---> a great time for them now ?Timestamp (black vertical line) : Mar 1 2020
---> Lockdowns worldwide due to Covid-19
- - - - - - - - - - - - - - - - - - - - - - - - - - -
GlaxoSmithKline plc (GSK)
LSE:GSK
GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in Brentford, England.
Price decrease of 9.50%
- - - - - - - - - - - - - - - - - - - - - - - - - - -
Sorrento Therapeutics Inc.
NASDAQ:SRNE
Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is based San Diego (Calif.), USA
Price increase of 230%
- - - - - - - - - - - - - - - - - - - - - - - - - - -
As an ever greater number of companies seek to provide vaccines and enter the lucrative race of who will provide what
and who will be awarded plush government contracts, we can see that not all Big Pharma stocks are shining, pricewise.
Time will tell but if hindsight can teach us something, it is that whoever invested in this rather obscure and not well known company
called 'Sorrento Therapeutics", the investment would have been more rewarding than a comparable investment into GlaxoSmithKline plc.
Words of wisdom: if you have extra cash lying around, do a careful and thorough analysis first.
That is true, at all time, and even more so now, in this Covid-branded and forever altered world.
Francois Normandeau
Institutional Research Director for ADX-BRIEFING
P.S.
Live Stream on TradingView on Friday, January 1, 2021, at 6 am NY time, open to all.
See you there.
Sorrento Therapeutics - SRNE technical AnalysisPrices are moving inside a channel and using the channel theory the idea is to go long - target Price 12 USD
Sorrento Therapeutics - SRNE technical AnalysisWill Sorrento Therapeutics (SRNE) Report Negative Q3 Earnings? If it will be the case, just hold that the price will reach the 6.0 usd dollar per share anf if the 6 USD support level will not be broken the idea is to go long.
Prices are moving inside a channel.
Sorrento Stock Analysis - Sorrento stock forecast today SRNE Technical Analysis - Hold.
The Trendline and EMA (with a length of 200) has been broken giving a signal of weakness of this Market. The idea is always to invest in the trend direction (bullish), but currently there are not a lot of signals to go long.
If 7.5 USD level will not be broken in the next days, perhaps the idea is to go long, or, vice versa, if the support will be broken the idea is to go short (this option is too Risky).
FUNDAMENTAL Analysis
Sorrento Therapeutics (NASDAQ:SRNE) is one of those stocks that's kind of like a lightning rod. That's apparent from the fact that over 22% of the biotech's outstanding shares were sold short as of Aug. 14, 2020. On the other hand, there are also many investors who feel strongly optimistic about Sorrento's growth prospects.
SRNEFor Sorrento's Fan. GL
Sorrento's COVI-TRACK FDA Registration: www.accessdata.fda.gov
Not a trading call, just sharing my view, Good Luck
SRNE - Sorrento Stock AnalysisTechnical Analysis - Hold - The idea would be to go long, but just wait the end of the price retracement before going long
Fundamental Analysis:
Shares of Sorrento Therapeutics (NASDAQ:SRNE) rallied on Thursday after the biopharmaceutical company said it would take action against an organization it claims fraudulently attempted to manipulate its stock price. As of 3 p.m. EDT, Sorrento's stock was up 5% after rising as much as 16.6% earlier in the day.
Sorrento Therapeutics Stock Analysis Hold Before Buying
Sorrento and partner Mount Sinai Health System are reportedly gearing up to evaluate STI-1499 as both a stand-alone therapy and part of an antibody cocktail designed to inhibit infection by the SARS-CoV-2 virus, which causes COVID-19. If successful, the antibody could be a big money-maker for the company. That's the good news.
The bad news is that Sorrento is far from the only company developing an antibody regimen for COVID-19. Eli Lilly and Regeneron Pharmaceuticals, for instance, are both pursuing similar types of treatments for the respiratory disease.
Sorrento Therapeutics $SRNEUnconfirmed double bottom for $SRNE. It needs to break $2.66 for target price
If you find my charts useful, please just "Like"
